THE Generic and Biosimilar Medicines Association (GBMA) has welcomed the two-year budget extension to its 2015 Strategic Agreement with the government, saying it gives certainty and predictability for the sector.
Described as "direct outcomes of collaborative discussions between GBMA and the government through the Generic Medicines Working Group (GMWG)", the organisation hailed the biosimilar uptake drivers, amendments to price disclosure and enhancements to prescribing software to prioritise generic brands.
GBMA Chair, Allan Tillack said these measures were "essential in the formation of a functioning and competitive biosimilars market, delivering PBS savings and increasing patient access to these life-changing treatments".
The above article was sent to subscribers in Pharmacy Daily's issue from 10 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 May 17
